A 10 billion yuan M&A fund for biomedical industry will also be set up.Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing.
For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing.The policy is favorable for surprise attack and seize the opportunity to get on the bus > >Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.
At the end of the year, Shanghai launched a big action in the field of mergers and acquisitions. Today, the General Office of the Shanghai Municipal People's Government issued the Action Plan for Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027) (hereinafter referred to as the Action Plan).Biomedicine, as one of the leading industries in Shanghai, has a scale of nearly one trillion yuan. In 2023, the industrial scale reached 933.732 billion yuan, an increase of 4.9%; Shanghai's biomedical industry chain is relatively complete, with many medical device enterprises and CRO, CMO and CSO enterprises. Therefore, Yuan Shuai believes that the Shanghai Municipal Government will set up a 10 billion yuan M&A fund for biomedical industry, which is expected to cultivate internationally competitive biomedical enterprises through mergers and acquisitions.
Strategy guide
12-13
Strategy guide